KDIGO guideline is the first specifically addressing autosomal dominant polycystic kidney disease (ADPKD) and focuses on some unique aspects of management.

SAN DIEGO - Regulus Therapeutics Inc . (NASDAQ:RGLS), a biopharmaceutical company currently trading at $1.17 per share, today announced significant clinical and regulatory advancements in its ...

study of RGLS8429 for Autosomal Dominant Polycystic Kidney Disease (ADPKD). The study evaluates RGLS8429 treatment across three different weight-based dose levels, including measuring changes in ...

Buoyed by encouraging data for its lead drug for autosomal dominant polycystic kidney disease, Regulus Therapeutics has moved swiftly to file a financing that will give it the finances needed to ...

Using a handheld dynamometer to assess hip flexion and abduction strength during dialysis was reliable and safe, researchers found in a cross-sectional study.“Subjects in stages 3 and 4 of [chronic ...

Shares of Regulus Therapeutics ( RGLS, Financials) fell 24% to $0.89 as of 12:39 p.m. GMT-5 on Wednesday following the ...

(RTTNews) - Regulus Therapeutics Inc. (RGLS) Wednesday announced positive clinical as well as regulatory updates from its autosomal dominant polycystic kidney disease (ADPKD) program.